Bausch + Lomb shares are lower in Friday trading as investors react to renewed attention on litigation risk after a securities-fraud investigation announcement dated March 13, 2026. While the move is not tied to a new company earnings release today, the headline can pressure sentiment in mid-cap healthcare names when there’s limited fresh fundamental news flow. (globenewswire.com)

The decline comes after the company’s most recent earnings update, when Bausch + Lomb reported fourth-quarter and full-year 2025 results and issued its 2026 outlook. With the stock now trading in the mid-teens, investors are balancing the company’s growth narrative in eye health against execution and profitability questions implied by forward guidance and margin targets. (ir.bausch.com)

Traders will be monitoring for any incremental developments that could turn today’s sentiment-driven slide into a bigger repricing—such as updates to legal proceedings, changes to the company’s outlook, or notable shifts in insider trading or institutional positioning. Any additional clarification in filings or investor communications could quickly change the tone given the stock’s recent volatility around headline risk. (stocktitan.net)